
|Videos|September 27, 2016 (Updated: October 7, 2020)
- Hematologic Malignancies: Polycythemia Vera
- Volume 3
- Issue 3
Significant Developments in Treating PV
Author(s)Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, discusses the most recent developments in diagnosing polycythemia vera.
Articles in this issue
over 9 years ago
Management of ET, PV Requires 2 Distinct Approachesover 9 years ago
Expert Discusses Recent Developments in Polycythemia VeraRelated Content
Advertisement



Safety and Antitumor Activity Revealed for T-Cell Engager XmAb819 in RCC
Published: | Updated:

Sarcomatoid Features May Be a Biomarker in Chromophobe RCC
Published: | Updated:

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma
Published: | Updated:



























